Abstract: A gas sensor (1) including a sensor element (10); a metallic shell (138); a tubular outer surface member (190) attached directly or indirectly to the metallic shell, constitutes an outer surface of the gas sensor, and extends toward a rear end side in relation to the metallic shell; and a tubular protection member (210, 220) which is detachably fixed to a fixation region C1, C2 of an outer circumference of the outer surface member. The protection member includes a first arc portion (212), a second arc portion (222), and a fixation portion (214,224) brought into contact with and is fixed to the fixation region. When the protection member fixed to the outer circumference of the outer surface member by fixing the fixation portion to the fixation region is viewed in the axial O direction, the first arc portion and the second arc portion cover in total at least 90% of the entire circumference of the outer surface of the outer surface member.

Abstract: A robot system includes a robot including a robot main body having a receiving unit that receives a predetermined operation, a control apparatus that controls actuation of the robot main body, and a transmitting unit that, when the receiving unit receives the operation, transmits information representing reception of the operation, and an instruction apparatus having a receiving unit that receives the information transmitted by the transmitting unit and a first reporting unit, and instructing the control apparatus to execute an operation program, wherein, when the instruction apparatus is in a condition with a right for control in which the instruction apparatus can instruct the control apparatus to execute the operation program, when the receiving unit receives the information, the first reporting unit reports that the instruction apparatus is in the condition with the right for control.

Abstract: A robot controller controlling a robot arm driven by a motor is provided. The robot controller includes: a first processing unit having a first control unit, a first storage unit, and a first system bus that couples the first control unit and the first storage unit together, the first processing unit acquiring target position information designated in a program causing the robot arm to operate; and a second processing unit having a second control unit, a second storage unit, and a second system bus that couples the second control unit and the second storage unit together, the second processing unit receiving the target position information from the first processing unit and generating a trajectory of the robot arm, based on the target position information.

Abstract: A robot control device according to an aspect of the invention is a robot control device that controls a robot on the basis of a simulation result of a simulation device that performs a simulation of operation of a virtual robot on a virtual space. In the simulation, a first region and a second region located on an inside of the first region can be set on the virtual space. In the case where the virtual robot operates, when a specific portion of the virtual robot intrudes into the first region, operating speed of the virtual robot is limited. When the specific portion of the virtual robot intrudes into the second region, the operation of the virtual robot stops or the virtual robot retracts from the second region.

Abstract: A robot system includes a robot including a robot main body having a receiving unit that receives a predetermined operation, a control apparatus that controls actuation of the robot main body, and a transmitting unit that, when the receiving unit receives the operation, transmits information representing reception of the operation, and an instruction apparatus having a receiving unit that receives the information transmitted by the transmitting unit and a first reporting unit, and instructing the control apparatus to execute an operation program, wherein, when the instruction apparatus is in a condition with a right for control in which the instruction apparatus can instruct the control apparatus to execute the operation program, when the receiving unit receives the information, the first reporting unit reports that the instruction apparatus is in the condition with the right for control.

Abstract: The present invention provides a nucleic acid having activity to suppress expression of MASP2, a pharmaceutical composition comprising the nucleic acid, and a prophylactic or therapeutic drug containing the nucleic acid for autoimmune diseases such as APS, SLE and the like and thrombosis in hemodialysis.

Abstract: A robot control device according to an aspect of the invention is a robot control device that controls a robot on the basis of a simulation result of a simulation device that performs a simulation of operation of a virtual robot on a virtual space. In the simulation, a first region and a second region located on an inside of the first region can be set on the virtual space. In the case where the virtual robot operates, when a specific portion of the virtual robot intrudes into the first region, operating speed of the virtual robot is limited. When the specific portion of the virtual robot intrudes into the second region, the operation of the virtual robot stops or the virtual robot retracts from the second region.

Abstract: A robot control device according to an aspect of the invention is a robot control device that controls a robot on the basis of a simulation result of a simulation device that performs a simulation of operation of a virtual robot on a virtual space. In the simulation, a first region and a second region located on an inside of the first region can be set on the virtual space. In the case where the virtual robot operates, when a specific portion of the virtual robot intrudes into the first region, operating speed of the virtual robot is limited. When the specific portion of the virtual robot intrudes into the second region, the operation of the virtual robot stops or the virtual robot retracts from the second region.

Abstract: The present invention aims to provide a novel nucleic acid capable of suppressing expression of ?2GPI, as well as a pharmaceutical composition for the prophylaxis or treatment of diseases associated with ?2GPI expression. The present invention solves the above-mentioned problem by providing an antisense oligonucleotide having a ?2GPI expression suppressive activity, a pharmaceutical composition containing the antisense oligonucleotide, and a prophylactic or therapeutic drug for autoimmune diseases including APS, SLE and the like, and thrombosis in hemodialysis that contains the antisense oligonucleotide and suppresses ?2GPI expression.

Abstract: The present invention provides a nucleic acid conjugate comprising: a double-stranded nucleic acid consisting of a sense strand and an antisense strand and comprising a duplex region of at least 11 base pairs; and a ligand part, wherein an oligonucleotide with a strand length of 17 to 30 nucleotides in the antisense strand is complementary to a target ?2GPI mRNA sequence, and the 3? end or 5? end of the sense strand has a ligand part represented by following formula (I), formula (II), formula (III), formula (IV) or formula (V).

Abstract: A robot control device according to an aspect of the invention is a robot control device that controls a robot on the basis of a simulation result of a simulation device that performs a simulation of operation of a virtual robot on a virtual space. In the simulation, a first region and a second region located on an inside of the first region can be set on the virtual space. In the case where the virtual robot operates, when a specific portion of the virtual robot intrudes into the first region, operating speed of the virtual robot is limited. When the specific portion of the virtual robot intrudes into the second region, the operation of the virtual robot stops or the virtual robot retracts from the second region.

Abstract: The present invention provides a nucleic acid having activity to suppress expression of ?2GPI, a pharmaceutical composition comprising the nucleic acid, and a prophylactic or therapeutic drug containing the nucleic acid for autoimmune diseases such as APS, SLE and the like and thrombosis in hemodialysis.

Abstract: The present invention provides a nucleic acid having activity to suppress expression of ?2GPI, a pharmaceutical composition comprising the nucleic acid, and a prophylactic or therapeutic drug containing the nucleic acid for autoimmune diseases such as APS, SLE and the like and thrombosis in hemodialysis.

Abstract: The present invention provides a nucleic acid having activity to suppress expression of ?2GPI, a pharmaceutical composition comprising the nucleic acid, and a prophylactic or therapeutic drug containing the nucleic acid for autoimmune diseases such as APS, SLE and the like and thrombosis in hemodialysis.

Abstract: An anti-CD4 antibody which binds to CD4, has a high affinity and has a high effector activity, such as an antibody-dependent cellular cytotoxicity (ADCC activity) or complement-dependent cellular cytotoxicity (CDC activity), is required for a disease relating to a CD4-expressing cell. The present invention can provide a monoclonal antibody or an antibody fragment thereof, which binds to a CD4 extracellular region with high affinity and also exhibits a high ADCC activity or a high CDC activity; a hybridoma which produces the antibody; a DNA which encodes the antibody; a vector which contains the DNA; a transformant obtainable by introducing the vector; a process for producing an antibody or an antibody fragment thereof using the hybridoma or the transformant; and a therapeutic agent using the antibody or the antibody fragment thereof or a diagnostic agent using the antibody or the antibody fragment thereof.

Abstract: Medicaments for treating diseases related to HB-EGF escalation are in demand. The present invention provides a method for producing a monoclonal antibody or an antibody fragment thereof which binds to a cell membrane-bound HB-EGF, a membrane type HB-EGF and a secretory HB-EGF.

Abstract: An anti-CD4 antibody which binds to CD4, has a high affinity and has a high effector activity, such as an antibody-dependent cellular cytotoxicity (ADCC activity) or complement-dependent cellular cytotoxicity (CDC activity), is required for a disease relating to a CD4-expressing cell. The present invention can provide a monoclonal antibody or an antibody fragment thereof, which binds to a CD4 extracellular region with high affinity and also exhibits a high ADCC activity or a high CDC activity; a hybridoma which produces the antibody; a DNA which encodes the antibody; a vector which contains the DNA; a transformant obtainable by introducing the vector; a process for producing an antibody or an antibody fragment thereof using the hybridoma or the transformant; and a therapeutic agent using the antibody or the antibody fragment thereof or a diagnostic agent using the antibody or the antibody fragment thereof.

Abstract: Medicaments for treating diseases related to HB-EGF escalation are in demand. The present invention provides a monoclonal antibody or an antibody fragment thereof which binds to a cell membrane-bound HB-EGF, a membrane type HB-EGF and a secretory HB-EGF.

Abstract: An anti-CD4 antibody which binds to CD4, has a high affinity and has a high effector activity, such as an antibody-dependent cellular cytotoxicity (ADCC activity) or complement-dependent cellular cytotoxicity (CDC activity), is required for a disease relating to a CD4-expressing cell. The present invention can provide a monoclonal antibody or an antibody fragment thereof, which binds to a CD4 extracellular region with high affinity and also exhibits a high ADCC activity or a high CDC activity; a hybridoma which produces the antibody; a DNA which encodes the antibody; a vector which contains the DNA; a transformant obtainable by introducing the vector; a process for producing an antibody or an antibody fragment thereof using the hybridoma or the transformant; and a therapeutic agent using the antibody or the antibody fragment thereof or a diagnostic agent using the antibody or the antibody fragment thereof.

Abstract: A mobile communication apparatus configured to communicate with an opposite communication device is provided. The mobile communication apparatus includes a transceiver configured to receive an incoming signal sent from the opposite communication device. The transceiver is configured to produce an interrupt signal upon receiving the incoming signal. The mobile communication apparatus includes a first memory device and a non-volatile second memory device. The mobile communication apparatus includes a controller connected to the transceiver, the first memory device and the second memory device. The controller is configured to perform garbage collection of the second memory device, to load data stored in one of the first memory device and the second memory device into another of the first memory device and the second memory device, to access the first memory device if the transceiver produces the interrupt signal.